<DOC>
	<DOCNO>NCT00534703</DOCNO>
	<brief_summary>The aim study determine safety feasibility give adeno-associated viral vector express sarcoplasmic reticulum calcium ATPase ( SERCA2a ) , drive CMV promoter ( AAV1-CMV-SERCA2a ) , heart failure patient receive left ventricular assist device ( LVAD ) accept clinical indication . It randomise , double-blind study 24 patient randomise receive either study drug ( AAV1.SERCA2a ) placebo . The purpose gene transfer SERCA2a improve systolic diastolic function fail ventricle . Studies show reduction SERCA2a fail ventricle key factor depression contraction , restoration SERCA2a level improve function near normal level . The vector deliver cardiac catheterisation procedure 10-minute infusion coronary artery . Myocardial tissue obtain time LVAD placement , routine part device implantation . Further sample obtain heart transplant LVAD remove . Measures tissue inflammation well efficacy gene transfer make compare two sample . Recovery contractile function heart assess attempt wean patient LVAD use standard protocol . The result assess conjunction two companion study start early US , one performing SERCA2a gene transfer vector , deliver direct injection myocardium LVAD insertion , one use AAV1-CMV-SERCA2a deliver percutaneously heart failure patient . The latter dose-ranging placebo-controlled arm .</brief_summary>
	<brief_title>Investigation Safety Feasibility AAV1/SERCA2a Gene Transfer Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion criterion Patients leave ventricular assist device ( LVAD ) implant chronic heart failure , chronic heart failure define least 6 month Patients clinically stable opinion clinical team look patient Written inform consent Exclusion criterion &lt; 18 &gt; 70 year age time consent Pregnancy within 6 month give birth Women childbearing potential use effective method contraception Men use effective method contraception Suspected active viral , fungal parasitic infection within 48 hour prior administration IMP , opinion investigator* . Patients high risk thrombosis opinion investigator Patients previous episode LVAD thrombosis Patients persistently raise lactate dehydrogenase ( LDH &gt; 2.5 ULN ) Patients require triple anticoagulation i.e . warfarin dual antiplatelet Patients participate another clinical trial Patients unable comply protocol mandate procedure social reason , opinion investigator primary care physician Eligible , enrol randomised patient develop infection study treatment delay 7 day time point infection longer clinically evident .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>